English

This guideline offers updated, evidence-based recommendations—from preconception through postpartum—on universal prenatal HIV testing, preferred antiretroviral regimens (e.g., bictegravir/TAF/FTC), maternal viral monitoring, obstetric management, and neonatal prophylaxis to further reduce perinatal HIV transmission toward elimination goals (defined as <1% transmission rate and <1 infection per 100,000 live births).

This information sheet offers an in-depth analysis of current AFP models—including funding mechanisms, stakeholder roles, and implementation strategies—to support sustainability of HIV-related services beyond traditional grant funding. It outlines key considerations and best practices to help health departments and community partners explore and launch innovative financing options for long-term epidemic response planning.

This toolkit supports Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Programs (ADAPs)—which provide access to HIV-related medications for low-income individuals—in navigating the planning, selection, and implementation of benefits management contracts. It offers key definitions, planning tools, real-world examples, and checklists to help ADAP administrators—new or experienced—align contractor selection with their program’s unique infrastructure and needs.

This webpage explains common causes—such as STIs, infections, or irritation—along with symptoms, diagnosis, and treatment options. It emphasizes the importance of timely medical care to address underlying issues and prevent complications.

In this webinar, CDC and HRSA speakers review the calendar year 2027–2031 Integrated HIV Prevention & Care Plan Guidance—highlighting key updates, submission requirements, and real-world recipient examples. The training equips CDC- and HRSA-funded jurisdictions with technical support, planning tools, and strategies to develop coordinated HIV prevention and care efforts by the June 30, 2026 deadline.

This guideline compiles up-to-date legal requirements across all U.S. states and territories, clarifying when healthcare providers and laboratories must report negative Hepatitis C test outcomes. It offers a clear, state-by-state breakdown to help public health entities and providers comply with surveillance obligations and improve data completeness.

This guideline presents a comprehensive state-by-state legal analysis of obligations for healthcare providers and laboratories to report negative HIV test outcomes. It clearly highlights jurisdictional differences, helping public health officials and clinicians ensure compliance with surveillance mandates and improve disease tracking.

GLP-1 receptor agonists (GLP-1s), including semaglutide, tirzepatide, and liraglutide, are increasingly used for weight management and show promise for people living with HIV (PLWH). While these medications are generally safe, PLWH may face additional considerations when using them due to how GLP-1s function and interact with antiretroviral therapy (ART). GLP-1s slow gastric emptying and suppress appetite, which may affect ART absorption; gastrointestinal side effects such as nausea or vomiting may also interfere with consistent ART dosing.

This infographic from Fair Health draws on data from its NPIC database—over 47 billion commercial medical and dental claims—to highlight rising trends in sexually transmitted disease (STD) diagnoses across various demographics in the U.S. between 2020 and 2023. The visuals show that overall STD diagnoses increased significantly, led by notable rises in syphilis, gonorrhea, and HIV/AIDS.

Tuberculosis (TB) remains the world’s deadliest infectious disease and a major treatment challenge, especially in cases resistant to standard therapies. A new AI-powered tool developed by Tufts University researchers, called DECIPHAER (Decoding Cross-Modal Information of Pharmacologies via Autoencoders), seeks to advance TB treatment by elucidating exactly how drugs kill the bacterium at the cellular and molecular levels.